ALX Oncology Holdings Inc. (ALXO) – What Are Researchers Saying About This Stock?

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have been assigned an average rating of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $4.60.

Separately, Weiss Ratings raised ALX Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently added to or reduced their stakes in the business. venBio Partners LLC acquired a new position in shares of ALX Oncology during the 2nd quarter valued at about $26,671,201. Redmile Group LLC lifted its holdings in shares of ALX Oncology by 143.9% during the 1st quarter. Redmile Group LLC now owns 7,964,188 shares of the company’s stock valued at $15,968,000 after acquiring an additional 4,699,470 shares in the last quarter. BlackRock Inc. purchased a new stake in shares of ALX Oncology in the second quarter worth about $15,317,000. Vivo Capital LLC purchased a new position in ALX Oncology in the 1st quarter worth approximately $6,385,000. Finally, 5AM Venture Management LLC purchased a new position in shares of ALX Oncology in the second quarter valued at $6,328,663. 97.97% of the stock is currently owned by hedge funds and other institutional investors.

ALX Oncology Trading Up 5.9%

Shares of ALX Oncology stock opened at $1.25 on Friday. ALX Oncology has a 12-month low of $1.05 and a 12-month high of $2.66. The stock has a market cap of $172.85 million, a PE ratio of -1.11 and a beta of 0.47. The company has a 50-day moving average of $1.78 and a two-hundred day moving average of $1.84. The company has a current ratio of 9.71, a quick ratio of 9.71 and a debt-to-equity ratio of 0.07.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.01. On average, research analysts anticipate that ALX Oncology will post -0.59 EPS for the current fiscal year.

About ALX Oncology

ALX Oncology Holdings Inc is a clinical-stage biopharmaceutical company focused on developing therapies that activate the immune system to fight cancer. The company’s research is centered on the CD47-SIRP? pathway, an innate immune checkpoint that cancer cells can use to avoid detection and destruction by immune cells.

Its lead investigational product is evorpacept, also known as ALX148, a protein therapeutic designed to block CD47 while limiting binding to red blood cells. Evorpacept is being evaluated in combination with other cancer treatments across several potential indications, including hematologic malignancies and solid tumors.